Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 4/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | PYGM | P11217 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.83 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.80 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.80 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.80 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.78 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.78 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.78 |
| ▸ | PTPRC | P08575 | 2/20 | 0.78 |
| ▸ | PTPRF | P10586 | 2/20 | 0.78 |
| ▸ | F3 | P13726 | 2/20 | 0.78 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.78 |
| ▸ | CES1 | P23141 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maslinic Acid SCHEMBL5797458 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Augustic Acid SCHEMBL829270 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL570425 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL3425459 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL24627035 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL13487363 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL19429613 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL22026389 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL21296155 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL14132395 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529452-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | Giuliani S.p.A. (IT) | 2025-04-02 | — | — | EP | disclosed |
| US-20250041318-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | COMMUNITREAT LTD. (IL) | 2025-02-06 | — | — | US | disclosed |
| EP-4440698-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | Communitreat Ltd. (IL) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024175703-A1 | COMPOSITION FOR IMPROVING THE AESTHETIC APPEARANCE OF HAIR AND SKIN APPENDAGES | GIULIANI S.P.A. (IT) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175702-A1 | COMPOSITION FOR IMPROVING THE AESTHETIC APPEARANCE OF HAIR AND SKIN APPENDAGES | GIULIANI S.P.A. (IT) | 2024-08-29 | — | — | WO | disclosed |
| US-20240198140-A1 | SYSTEMS AND METHODS FOR COMBINED COSMETIC TREATMENT OF CELLULITE WITH ULTRASOUND | ULTHERA, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11944849-B2 | Systems and methods for combined cosmetic treatment of cellulite with ultrasound | ULTHERA, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023228079-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023100184-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | COMMUNITREAT LTD. (IL) | 2023-06-08 | — | — | WO | disclosed |
| EP-4125414-A1 | FEED ADDITIVE | Lucta, S.A. (ES) | 2023-02-08 | — | — | EP | disclosed |
| EP-3532008-B1 | THE COSMETIC TREATMENT OF CELLULITE | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240198140-A1 | SYSTEMS AND METHODS FOR COMBINED COSMETIC TREATMENT OF CELLULITE WITH ULTRASOUND | CUTA, DNASE1, CASP14 | PTPN1 3114/4885PTPN2 3134/4885AKR1B10 3379/4885 |
| US-20250041318-A1 | STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF | NASP, ACR, ALPG | PTPN1 3079/4885PTPN2 3423/4885AKR1B10 425/4885 |
| US-11944849-B2 | Systems and methods for combined cosmetic treatment of cellulite with ultrasound | CUTA, DSTN, MMP1 | PTPN1 3261/4885PTPN2 3287/4885AKR1B10 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.